463 related articles for article (PubMed ID: 30093454)
1. Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab.
Raja R; Kuziora M; Brohawn PZ; Higgs BW; Gupta A; Dennis PA; Ranade K
Clin Cancer Res; 2018 Dec; 24(24):6212-6222. PubMed ID: 30093454
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors.
van der Leest P; Hiddinga B; Miedema A; Aguirre Azpurua ML; Rifaela N; Ter Elst A; Timens W; Groen HJM; van Kempen LC; Hiltermann TJN; Schuuring E
Mol Oncol; 2021 Nov; 15(11):2910-2922. PubMed ID: 34449963
[TBL] [Abstract][Full Text] [Related]
3. Variant allele frequency in circulating tumor DNA correlated with tumor disease burden and predicted outcomes in patients with advanced breast cancer.
Zhong J; Jiang H; Liu X; Liao H; Xie F; Shao B; Jia S; Li H
Breast Cancer Res Treat; 2024 Apr; 204(3):617-629. PubMed ID: 38183515
[TBL] [Abstract][Full Text] [Related]
4. Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Vega DM; Nishimura KK; Zariffa N; Thompson JC; Hoering A; Cilento V; Rosenthal A; Anagnostou V; Baden J; Beaver JA; Chaudhuri AA; Chudova D; Fine AD; Fiore J; Hodge R; Hodgson D; Hunkapiller N; Klass DM; Kobie J; Peña C; Pennello G; Peterman N; Philip R; Quinn KJ; Raben D; Rosner GL; Sausen M; Tezcan A; Xia Q; Yi J; Young AG; Stewart MD; Carpenter EL; Aggarwal C; Allen J
JCO Precis Oncol; 2022 Aug; 6():e2100372. PubMed ID: 35952319
[TBL] [Abstract][Full Text] [Related]
5. Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy.
Araujo DV; Wang A; Torti D; Leon A; Marsh K; McCarthy A; Berman H; Spreafico A; Hansen AR; Razak AA; Bedard PL; Wang L; Plackmann E; Chow H; Bao H; Wu X; Pugh TJ; Siu LL
JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 34056539
[TBL] [Abstract][Full Text] [Related]
6. Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer.
Tolmeijer SH; van Wilpe S; Geerlings MJ; von Rhein D; Smilde TJ; Kloots ISH; Westdorp H; Coskuntürk M; Oving IM; van Ipenburg JA; van der Heijden AG; Hofste T; Weiss MM; Schalken JA; Gerritsen WR; Ligtenberg MJL; Mehra N
Eur Urol Oncol; 2024 Apr; 7(2):282-291. PubMed ID: 37673768
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay.
Belloum Y; Janning M; Mohme M; Simon R; Kropidlowski J; Sartori A; Irwin D; Westphal M; Lamszus K; Loges S; Riethdorf S; Pantel K; Wikman H
Cells; 2020 Oct; 9(11):. PubMed ID: 33105541
[TBL] [Abstract][Full Text] [Related]
8. Identification of germline cancer predisposition variants during clinical ctDNA testing.
Stout LA; Kassem N; Hunter C; Philips S; Radovich M; Schneider BP
Sci Rep; 2021 Jul; 11(1):13624. PubMed ID: 34211039
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade.
Zhang Q; Luo J; Wu S; Si H; Gao C; Xu W; Abdullah SE; Higgs BW; Dennis PA; van der Heijden MS; Segal NH; Chaft JE; Hembrough T; Barrett JC; Hellmann MD
Cancer Discov; 2020 Dec; 10(12):1842-1853. PubMed ID: 32816849
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Validity of Urinary Pellet DNA Monitoring for the Diagnosis of Recurrent Bladder Cancer.
Abe M; Hiraki H; Tsuyukubo T; Ono S; Maekawa S; Tamura D; Yashima-Abo A; Kato R; Fujisawa H; Iwaya T; Park WY; Idogawa M; Tokino T; Obara W; Nishizuka SS
J Mol Diagn; 2024 Apr; 26(4):278-291. PubMed ID: 38301868
[TBL] [Abstract][Full Text] [Related]
11. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.
Vandekerkhove G; Lavoie JM; Annala M; Murtha AJ; Sundahl N; Walz S; Sano T; Taavitsainen S; Ritch E; Fazli L; Hurtado-Coll A; Wang G; Nykter M; Black PC; Todenhöfer T; Ost P; Gibb EA; Chi KN; Eigl BJ; Wyatt AW
Nat Commun; 2021 Jan; 12(1):184. PubMed ID: 33420073
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer.
Sivapalan L; Iams WT; Belcaid Z; Scott SC; Niknafs N; Balan A; White JR; Kopparapu P; Cann C; Landon BV; Pereira G; Velculescu VE; Hann CL; Lovly CM; Anagnostou V
Clin Cancer Res; 2023 Jun; 29(12):2310-2323. PubMed ID: 37071497
[TBL] [Abstract][Full Text] [Related]
13. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy and prognosis in breast cancer patients during primary systemic therapy.
Wang R; Wang B; Zhang H; Liao X; Shi B; Zhou Y; Zhou C; Yan Y; Zhang W; Wang K; Ge G; Ren Y; Tang X; Gan B; He J; Niu L
Breast; 2024 Apr; 76():103738. PubMed ID: 38685149
[TBL] [Abstract][Full Text] [Related]
14. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.
Assaf ZJF; Zou W; Fine AD; Socinski MA; Young A; Lipson D; Freidin JF; Kennedy M; Polisecki E; Nishio M; Fabrizio D; Oxnard GR; Cummings C; Rode A; Reck M; Patil NS; Lee M; Shames DS; Schulze K
Nat Med; 2023 Apr; 29(4):859-868. PubMed ID: 36928816
[TBL] [Abstract][Full Text] [Related]
15. Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer.
Semenkovich NP; Samson PP; Badiyan SN; Vlacich G; Stowe HB; Wang YE; Star R; Devarakonda S; Govindan R; Waqar SN; Robinson CG; Pellini B; Chaudhuri AA
Res Sq; 2023 Mar; ():. PubMed ID: 36993328
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer.
Carrasco R; Ingelmo-Torres M; Trullas R; Roldán FL; Rodríguez-Carunchio L; Juez L; Sureda J; Alcaraz A; Mengual L; Izquierdo L
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068899
[TBL] [Abstract][Full Text] [Related]
17. Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer.
Murray JC; Sivapalan L; Hummelink K; Balan A; White JR; Niknafs N; Rhymee L; Pereira G; Rao N; Weksler B; Bahary N; Phallen J; Leal A; Bartlett DL; Marrone KA; Naidoo J; Goel A; Levy B; Rosner S; Hann CL; Scott SC; Feliciano J; Lam VK; Ettinger DS; Li QK; Illei PB; Monkhorst K; Scharpf RB; Brahmer JR; Velculescu VE; Zaidi AH; Forde PM; Anagnostou V
Clin Cancer Res; 2024 Jan; 30(2):389-403. PubMed ID: 37939140
[TBL] [Abstract][Full Text] [Related]
18.
Francis JH; Gobin YP; Brannon AR; Swartzwelder CE; Berger MF; Mandelker DL; Walsh MF; Dunkel IJ; Abramson DH
Ophthalmol Sci; 2021 Sep; 1(3):100042. PubMed ID: 36247821
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Comparative Analysis of Circulating Tumor DNA and Matched Tumor Tissue DNA in Patients with Metastatic Colorectal Cancer Receiving Palliative First-Line Systemic Anti-Cancer Therapy.
Lee SB; Kim JW; Kim HG; Hwang SH; Kim KJ; Lee JH; Seo J; Kang M; Jung EH; Suh KJ; Kim SH; Kim JW; Kim YJ; Kim JH; Kwon NJ; Lee KW
Cancer Res Treat; 2024 Apr; ():. PubMed ID: 38697850
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma.
Guibert N; Mazieres J; Delaunay M; Casanova A; Farella M; Keller L; Favre G; Pradines A
Oncotarget; 2017 Jun; 8(23):38056-38060. PubMed ID: 28445137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
